Scinai Immunotherapeutics Gets Italian Clearance for Pincell Acquisition
Ticker: SCNI · Form: 6-K · Filed: 2025-06-05T00:00:00.000Z
Sentiment: bullish
Topics: acquisition, regulatory-approval, biotech
TL;DR
Scinai got the green light from Italy for the Pincell deal. Big step forward!
AI Summary
On June 5, 2025, Scinai Immunotherapeutics Ltd. announced it has received Italian government clearance for its potential acquisition of Pincell S.r.l. This clearance is a significant step towards completing the acquisition.
Why It Matters
This regulatory approval from the Italian government is a crucial step forward in Scinai's strategy to acquire Pincell S.r.l., potentially impacting its future growth and market position.
Risk Assessment
Risk Level: medium — While regulatory clearance is positive, the acquisition is still 'potential' and subject to further conditions, indicating ongoing risk.
Key Players & Entities
- Scinai Immunotherapeutics Ltd. (company) — Filer of the report and acquirer
- Pincell S.r.l. (company) — Target company for acquisition
- June 5, 2025 (date) — Date of the press release announcing clearance
- Italian government (company) — Regulatory body granting clearance
FAQ
What specific Italian government entity granted the clearance?
The filing states 'Italian government clearance' but does not specify the exact governmental body.
What are the remaining conditions for the acquisition of Pincell S.r.l.?
The filing mentions 'potential acquisition' and 'clearance' but does not detail the remaining conditions.
When was the press release announcing the clearance issued?
The press release was issued on June 5, 2025.
Is this acquisition a done deal now that clearance has been received?
No, the filing refers to a 'potential acquisition,' implying that clearance is a step, but not necessarily the final one.
What is the primary business of Pincell S.r.l.?
The filing does not provide details on the business of Pincell S.r.l.
From the Filing
0001213900-25-051478.txt : 20250605 0001213900-25-051478.hdr.sgml : 20250605 20250605133148 ACCESSION NUMBER: 0001213900-25-051478 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20250605 FILED AS OF DATE: 20250605 DATE AS OF CHANGE: 20250605 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Scinai Immunotherapeutics Ltd. CENTRAL INDEX KEY: 0001611747 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: L3 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37353 FILM NUMBER: 251026502 BUSINESS ADDRESS: STREET 1: JERUSALEM BIOPARK, 2ND FLOOR STREET 2: HADASSAH EIN KEREM CAMPUS CITY: JERUSALEM STATE: L3 ZIP: 00000 BUSINESS PHONE: 972-8-9302529 MAIL ADDRESS: STREET 1: JERUSALEM BIOPARK, 2ND FLOOR STREET 2: HADASSAH EIN KEREM CAMPUS CITY: JERUSALEM STATE: L3 ZIP: 00000 FORMER COMPANY: FORMER CONFORMED NAME: BiondVax Pharmaceuticals Ltd. DATE OF NAME CHANGE: 20140624 6-K 1 ea0244840-6k_scinai.htm REPORT OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of June 2025 Commission File Number: 001-37353 SCINAI IMMUNOTHERAPEUTICS LTD. (Translation of registrant’s name into English) Jerusalem BioPark, 2nd Floor Hadassah Ein Kerem Campus Jerusalem, Israel (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F ☒ Form 40-F ☐ Explanatory Note On June 5, 2025, Scinai Immunotherapeutics Ltd. issued a press release announcing receipt of Italian government clearance for the potential acquisition of Pincell S.r.l. A copy of the press release is furnished herewith as Exhibit 99.1. This Report on Form 6-K is hereby incorporated by reference into the registrant’s Registration Statements on Form S-8 (File No. 333-271293 and File No. 333-239344 ) and Form F-3 (File No. 333-274078 and File No. 333-276767 ), to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished. Exhibit Index Exhibit No. Description 99.1 Press release dated June 5, 2025. 1 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Scinai Immunotherapeutics Ltd. Date: June 5, 2025 By: /s/ Amir Reichman Amir Reichman Chief Executive Officer 2 EX-99.1 2 ea024484001ex99-1_scinai.htm PRESS RELEASE DATED JUNE 5, 2025 Exhibit 99.1 Scinai Immunotherapeutics Receives Italian Government Clearance Under Golden Power Regulation for Potential Acquisition of Pincell S.r.l. The regulatory approval marks a key milestone toward the potential acquisition of Pincell, removing a major condition precedent under the option agreement and allowing Scinai to advance toward finalizing the transaction, subject to customary remaining conditions. JERUSALEM, June 5, 2025 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), a biopharmaceutical company specializing in inflammation and immunology (I&I) biological products and providing CDMO services through its Scinai Bioservices unit, today announced that the Italian government has granted clearance under the Golden Power regulation (Law Decree No. 21/2012) for Scinai's option to acquire 100% of the share capital and voting rights of Pincell S.r.l., an Italian biotechnology company. This approval was issued following a review by the Coordination Group for the exercise of special powers, based on the outcome of the assessment conducted by the Ministry of Health, the competent authority. The clearance pertains to the transaction as presen